165 related articles for article (PubMed ID: 37020793)
1. Ceftazidime-Avibactam Treatment for Severe Post-Neurosurgical Meningitis and Abscess Caused by Extended-Spectrum β-Lactamase
Ren J; Wang Q; Liu L; Xiao Y; Ji P; Du H; Wang S; Zheng Y; Yang Q
Infect Drug Resist; 2023; 16():1905-1911. PubMed ID: 37020793
[TBL] [Abstract][Full Text] [Related]
2. Utilizing Ceftazidime/Avibactam Therapeutic Drug Monitoring in the Treatment of Neurosurgical Meningitis Caused by Difficult-to-Treat Resistant
Yasmin M; Nutman A; Wang L; Marshall S; Chen K; Wang J; Yahav D; Lupinsky L; Hujer AM; Bhimraj A; van Duin D; Li J; Bonomo RA
Open Forum Infect Dis; 2023 Nov; 10(11):ofad507. PubMed ID: 38023540
[TBL] [Abstract][Full Text] [Related]
3. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.
Torres-Castillo LC; Fandiño C; Ramos MP; Ramos-Castaneda JA; Rioseco ML; Juliet C
J Glob Antimicrob Resist; 2023 Dec; 35():143-148. PubMed ID: 37714380
[TBL] [Abstract][Full Text] [Related]
5. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S; Wang H; Feng S
Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
[TBL] [Abstract][Full Text] [Related]
6. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
[TBL] [Abstract][Full Text] [Related]
8. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review.
Zhou Q; Wang H; Zhan T; Yang X; Wen L
Infect Drug Resist; 2021; 14():1691-1701. PubMed ID: 33981150
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa.
Xu C; Zeng F; Huang Y; Xu Q; Yang Y; Gong W; Shi C; Zhang Y
Int J Antimicrob Agents; 2024 Jan; 63(1):107021. PubMed ID: 37890733
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant
Kim T; Lee SC; Bae M; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Chong YP
Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33334045
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
Chen Y; Huang HB; Peng JM; Weng L; Du B
Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
[TBL] [Abstract][Full Text] [Related]
13. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli.
Chen W; Sun L; Guo L; Cao B; Liu Y; Zhao L; Lu B; Li B; Chen J; Wang C
Ann Transl Med; 2020 Feb; 8(3):39. PubMed ID: 32154284
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa.
Corbella L; Boán J; San-Juan R; Fernández-Ruiz M; Carretero O; Lora D; Hernández-Jiménez P; Ruiz-Ruigómez M; Rodríguez-Goncer I; Silva JT; López-Medrano F; Lizasoain M; Villa J; Caro-Teller JM; Aguado JM
Int J Antimicrob Agents; 2022 Feb; 59(2):106517. PubMed ID: 34990760
[TBL] [Abstract][Full Text] [Related]
16. Implementation of Chromatic Super CAZ/AVI
Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
[TBL] [Abstract][Full Text] [Related]
17. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam.
Yang X; Wang D; Zhou Q; Nie F; Du H; Pang X; Fan Y; Bai T; Xu Y
BMC Microbiol; 2019 Nov; 19(1):240. PubMed ID: 31675928
[TBL] [Abstract][Full Text] [Related]
19. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies.
Di Bella S; Giacobbe DR; Maraolo AE; Viaggi V; Luzzati R; Bassetti M; Luzzaro F; Principe L
J Glob Antimicrob Resist; 2021 Jun; 25():268-281. PubMed ID: 33895414
[TBL] [Abstract][Full Text] [Related]
20. Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.
Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
